The treatment gap in coronary artery disease and heart failure: Community standards and the post-discharge patient

American Journal of Cardiology

Volumn 80, Issue 8 B, 1997, Pages

  Pearson, Thomas A ^a   Peters, Theodore D ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b BASSETT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

CONFERENCE PAPER; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEART FAILURE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RISK ASSESSMENT;

EID: 0030731821     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00820-5     Document Type: Conference Paper

References (32)

1. Fuster V, Gotto AM Jr, Libby P, Loscalzo J, McGill HC. Pathogenesis of coronary disease the biologic role of risk factors . 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol. 27:1996;964-976.
2. Pasternak RC, Grundy SM, Levy D, Thompson PD. Spectrum of risk factors for coronary heart disease. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol. 27:1996;976-978.
3. Forrester JS, Bairey Merz CN Bush TL, Cohn JN, Hunninghake DB, Parthasarathy S, Superko R. Efficacy of risk factor management. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol. 27:1996;991-1006.
4. Goldman L, Garber AM, Grover SA, Hlatky MA. Cost effectiveness of assessment and management of risk factors. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol. 27:1996;1020-1030.
5. Brown MS, Goldstein JL. Heart attacks gone with the century? Science. 272:1996;629.
6. Smith SC, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould L, Greenland P, Grundy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD. Preventing heart attack and death in patients with coronary disease. Circulation. 92:1995;2-4.
7. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease ASPIRE (Action in Secondary Prevention through Intervention to Reduce Events) . Principal Results. Heart. 75:1996;334-342.
8. EUROASPIRE Steering Committee, personal communication, 1996.
9. Schucker B, personal communication, 1996.
10. Cohen MV, Byrne M-J, Levine B, Gutowski Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation. 83:1991;1294-1304.
11. Pearson TA, Kris-Etherton PM, Shannon BM, Lewis C, Jenkins PL. Attainment of low density lipoprotein (LDL) cholesterol goals in primary care practice success depends on baseline level of risk . (Abstr.) Circulation. 94:1996;I-177.
12. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3033.
13. Vogel RA. Risk factor intervention and coronary artery disease clinical strategies . Coronary Artery Disease. 6:1995;466-471.
14. Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE. Adjunctive drug therapy of acute myocardial infarction. Evidence from clinical trials. N Engl J Med. 335:1996;1660-1667.
15. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel BJ, Russell RO, Smith EE III, Weaver D. ACC/AHA guidelines for the management of patients with acute myocardial infarction executive summary . Circulation. 94:1996;2341-2350.
16. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States time for a different approach . J Heart Lung Transplant. 13:1994;S107-S112.
17. Rajfer SI. Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol. 22:(suppl A):1993;198A-200A.
18. Philbin EF, Andreou C, Rocco TA Jr, Lynch LJ, Baker SL. Patterns of angiotensin converting enzyme inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol. 77:1996;832-838.
19. Konstam MA, Dracup K, Bottoroff MB, Brooks NH, Cacey RA, Dunbar SB, Jackson AB, Jessup M, Johnson JC, Jones RH, Luchi RJ, Massie BM, Pitt B, Rose EA, Rubin LJ, Wright RF. Quick Reference Guide For Clinicians No. 11: Heart Failure: Management of Patients With Left Ventricular Systolic Dysfunction. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, United States Department of Health and Human Services, 1994. AHCPR (publication no. 94-0613).
20. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by healthcare providers. Am J Med. 100:1996;605-610.
21. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease Factors limiting achievement of lipid goals . Am J Med. 100:1996;197-204.
22. Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice a systematic review of rigorous evaluations . Lancet. 342:1993;1317-1322.
23. Epstein A. Performance reports on quality - prototypes, problems, and prospects. N Engl J Med. 333:1993;57-61.
24. Committee on Performance Measurement of the National Center for Quality Assurance. Health Plan Employer Data and Information Set. HEDIS 3.0 Draft, 1996.
25. Pearson TA, McBride PE, Houston Miller N Smith SC. Organization of preventive cardiology service. 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol. 27:1996;1039-1047.
26. Kaplan GA, Keil JE. Socioeconomic factors and cardiovascular disease a review of the literature . Circulation. 88:1995;1973-1998.
27. Williams RB, Barefoot JC, Califf RM, Haney TL, Saunders WB, Pryor DB, Hlatky MA, Siegler IC, Mark DB. Prognostic importance of social and economic resources among medically treated patients with angiographically defined coronary heart disease. JAMA. 267:1992;520-524.
28. Levine DM. Behavioral and psychosocial factors, processes and strategies. Pearson TA. 1994;217-226 American Heart Association, Criqui MH, Luepker RV, Oberman A, Winston M. eds. Primer in Preventive Cardiology. Dallas.
29. Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shelvin N. Medication compliance a health care problem . Ann Pharmacother. 27:(suppl):1993;S2-S22.
30. Shea S, Gemson DH, Mossel P. Management of high blood cholesterol by primary care physicians diffusion of the National Cholesterol Education Program Adult Treatment Panel guidelines . J Gen Intern Med. 5:1990;327-334.
31. Roberts WC. Getting cardiologists interested in lipids. Am J Cardiol. 72:1993;744-745.
32. Genest J. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 67:1991;1185-1190.